Skip to main navigation Skip to search Skip to main content

Precision Medicine in Liver Cancer a National Consortium for Spatial and molecular Phenotyping of HCC

  • George, Jacob (Primary Chief Investigator (PCI))
  • Sharma, Ankur (Chief Investigator (CI))
  • Roberts, Stuart (Chief Investigator (CI))
  • Strasser, Simone Irene (Chief Investigator (CI))
  • Wigg, Alan (Chief Investigator (CI))
  • Majumdar, Avik (Chief Investigator (CI))
  • Howell, Jess (Chief Investigator (CI))
  • Stuart, Katherine Anne (Chief Investigator (CI))
  • Zekry, Amany (Chief Investigator (CI))
  • Levy, Miriam Tania (Chief Investigator (CI))

Project: Research

Project Details

Project Description

This national collaborative venture will establish a first-in-world cohort PRECISION (Precision Medicine in Liver Cancer a National Consortium for Advanced Spatial and Molecular Phenotyping of HCC) backed by an outstanding scientific team to profile and analyse cellular signatures across all liver cancer stages to maximise the potential of the rapidly evolving therapies to deliver precision medicine, while limiting adverse effects.
Trial objectives
1. PRECISIONx050: Use the oncofetal score developed in-house as a biomarker of immunotherapy response in early HCC
2. Use CELLOGRAM, a digital pathology based test for patient stratification
3. PRECISIONx150: use circulating T-cells as a biomarker of response in advanced HCC
4. Develop circulating-tumour (ct) DNA signatures as predictors of response to immunotherapy
Short titlePrecision Medicine in Liver Cancer
AcronymPRECISIONx050 and PRECISIONX150
StatusActive
Effective start/end date1/07/24 → 30/06/29